Evanson Asset Management LLC Takes $475,000 Position in Beta Bionics, Inc. (NASDAQ:BBNX)

Evanson Asset Management LLC bought a new position in shares of Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 38,772 shares of the company's stock, valued at approximately $475,000. Evanson Asset Management LLC owned about 0.09% of Beta Bionics as of its most recent filing with the Securities & Exchange Commission.

Separately, Rhumbline Advisers bought a new stake in shares of Beta Bionics during the 1st quarter valued at about $158,000.

Beta Bionics Price Performance

Beta Bionics stock opened at $17.78 on Friday. The firm has a 50-day moving average of $14.51. Beta Bionics, Inc. has a 1 year low of $8.89 and a 1 year high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on BBNX shares. Leerink Partnrs upgraded Beta Bionics to a "strong-buy" rating in a report on Monday, February 24th. Wolfe Research began coverage on shares of Beta Bionics in a report on Friday, May 30th. They issued an "outperform" rating and a $20.00 price objective for the company. Robert W. Baird started coverage on shares of Beta Bionics in a research report on Thursday, February 20th. They set a "neutral" rating and a $20.00 target price for the company. The Goldman Sachs Group assumed coverage on Beta Bionics in a report on Friday, May 30th. They set a "neutral" rating and a $16.00 price target on the stock. Finally, Baird R W upgraded Beta Bionics to a "hold" rating in a research report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Beta Bionics has an average rating of "Moderate Buy" and an average target price of $23.44.

Insider Transactions at Beta Bionics

In related news, CFO Stephen Feider sold 1,497 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $26,781.33. Following the sale, the chief financial officer now owns 45,503 shares of the company's stock, valued at $814,048.67. This trade represents a 3.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last 90 days, insiders have sold 4,519 shares of company stock valued at $80,845.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.